PMV Pharmaceuticals annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
PMV Pharmaceuticals Stock-Based Compensation Growth & History (PMVP)
PMV Pharmaceuticals's stock-based compensation was $5.9M for fiscal 2025.
View full PMV Pharmaceuticals company overviewPMV Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.9M | −$2.9M | −33.23% |
| 2024 | 2024-12-31 | $8.9M | −$3.5M | −28.31% |
| 2023 | 2023-12-31 | $12.4M | $2.2M | +21.38% |
| 2022 | 2022-12-31 | $10.2M | $4.9M | +90.92% |
| 2021 | 2021-12-31 | $5.3M | $3.4M | +176.25% |
| 2020 | 2020-12-31 | $1.9M | $1.0M | +112.89% |
| 2019 | 2019-12-31 | $908,000 | −$171,000 | −15.85% |
| 2018 | 2018-12-31 | $1.1M | — | — |
PMV Pharmaceuticals quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.5M | −$125,000 | −7.49% |
| Q1 2026 | 2026-03-31 | $1.4M | −$116,000 | −7.69% |
| Q4 2025 | 2025-12-31 | $1.4M | $94,000 | +7.40% |
| Q3 2025 | 2025-09-30 | $1.4M | −$841,000 | −37.81% |
| Q2 2025 | 2025-06-30 | $1.7M | −$1.1M | −39.72% |
| Q1 2025 | 2025-03-31 | $1.5M | −$1.1M | −42.22% |
| Q4 2024 | 2024-12-31 | $1.3M | −$1.7M | −57.15% |
| Q3 2024 | 2024-09-30 | $2.2M | −$1.1M | −33.09% |
| Q2 2024 | 2024-06-30 | $2.8M | −$386,000 | −12.24% |
| Q1 2024 | 2024-03-31 | $2.6M | −$322,000 | −10.98% |
| Q4 2023 | 2023-12-31 | $3.0M | −$86,000 | −2.82% |
| Q3 2023 | 2023-09-30 | $3.3M | $876,000 | +35.78% |
| Q2 2023 | 2023-06-30 | $3.2M | $635,000 | +25.22% |
| Q1 2023 | 2023-03-31 | $2.9M | $755,000 | +34.68% |
| Q4 2022 | 2022-12-31 | $3.1M | $1.3M | +72.72% |
| Q3 2022 | 2022-09-30 | $2.4M | $652,000 | +36.30% |
| Q2 2022 | 2022-06-30 | $2.5M | $1.4M | +118.96% |
| Q1 2022 | 2022-03-31 | $2.2M | $1.6M | +247.21% |
| Q4 2021 | 2021-12-31 | $1.8M | $1.2M | +202.57% |
| Q3 2021 | 2021-09-30 | $1.8M | $1.1M | +168.06% |
| Q2 2021 | 2021-06-30 | $1.1M | $767,000 | +200.26% |
| Q1 2021 | 2021-03-31 | $627,000 | $331,000 | +111.82% |
| Q4 2020 | 2020-12-31 | $584,000 | — | — |
| Q3 2020 | 2020-09-30 | $670,000 | $431,000 | +180.33% |
| Q2 2020 | 2020-06-30 | $383,000 | — | — |
| Q1 2020 | 2020-03-31 | $296,000 | — | — |
| Q3 2019 | 2019-09-30 | $239,000 | — | — |
PMV Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, PMV Pharmaceuticals's stock-based compensation increased from $1.9M to $5.9M, a change of $4.0M. The latest reported quarter, Q2 2026, shows $1.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PMV Pharmaceuticals source filings ↗